STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13D/A] Trevi Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A
Rhea-AI Filing Summary

NEA amendments report current holdings and a dilution-driven decrease in stake. The filing discloses that New Enterprise Associates and affiliated reporting persons collectively beneficially own 15,074,080 shares of Trevi Therapeutics common stock, representing 12.0% of the outstanding class on the basis stated in the filing. NEA 16 is shown as the record owner of 10,421,428 shares and as holding warrants exercisable for 3,703,704 shares; NEA 18 VGE holds 948,948 shares. The ownership figures reflect shared voting and dispositive power among the reporting entities and individuals.

The amendment explains the decrease in the percentage ownership as resulting from an increase in the number of shares outstanding, and reiterates that the Funds acquired the shares for investment purposes. The filing states there are no present plans by the reporting persons to pursue corporate actions such as board changes, asset sales, or extraordinary transactions, and notes that no transactions were effected by the reporting persons in the last 60 days. Exhibits include the joint filing agreement and a power of attorney.

Positive
  • Collective beneficial ownership of 15,074,080 shares (12.0%) provides a clear, material stake in Trevi Therapeutics.
  • NEA 16 holds 10,421,428 record shares plus warrants for 3,703,704 shares, showing current holdings and potential future economic interest.
  • Filing explicitly states shares were acquired for investment purposes and disclaims present plans for corporate control actions, reducing immediate governance uncertainty.
Negative
  • Reported beneficial ownership decreased by more than 1% due to an increase in the number of shares outstanding, indicating dilution of stake.
  • All reporting persons report shared voting and dispositive power (no sole power), which may limit any individual reporting person’s unilateral control influence.

Insights

NEA retains a meaningful 12% stake but was diluted; no activist intentions disclosed.

The filing confirms NEA and affiliated entities collectively beneficially own 15,074,080 shares (12.0%), including warrants that add potential dilution. That stake size is large enough to influence investor perception of shareholder composition yet the amendment explicitly attributes a greater-than-1% decline in ownership percentage to an increase in shares outstanding rather than sale of holdings. The Funds state acquisition was for investment purposes and disclaim any current plans to change board composition or pursue corporate transactions, which reduces near-term governance risk. Investors should note the combination of record ownership and outstanding warrants when assessing potential future dilution and voting dynamics.

Shared voting/dispositive power across NEA entities creates coordinated influence without declared control actions.

The amendment details that voting and dispositive power over the Firm Shares is shared among multiple NEA entities and managers, and that individual reporting persons report no sole voting or dispositive power. The filing expressly denies present plans for board changes, asset sales, or other extraordinary transactions, and includes agreements governing joint filing and a power of attorney. From a governance standpoint, the disclosure clarifies ownership structure and intent: substantial collective ownership exists but no immediate control agenda is disclosed, making the filing informative but not an indicator of imminent governance activism.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


New Enterprise Associates 16, L.P.
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
Date:08/11/2025
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:08/11/2025
NEA Partners 16, L.P.
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
Date:08/11/2025
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:08/11/2025
NEA 16 GP, LLC
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
Date:08/11/2025
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:08/11/2025
NEA 18 Venture Growth Equity, L.P.
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
Date:08/11/2025
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:08/11/2025
NEA Partners 18 VGE, L.P.
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
Date:08/11/2025
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:08/11/2025
NEA 18 VGE GP, LLC
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
Date:08/11/2025
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:08/11/2025
Forest Baskett
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Forest Baskett
Date:08/11/2025
Ali Behbahani
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Ali Behbahani
Date:08/11/2025
Carmen Chang
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Carmen Chang
Date:08/11/2025
Anthony A. Florence, Jr.
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr.
Date:08/11/2025
Mohamad H. Makhzoumi
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi
Date:08/11/2025
Scott D. Sandell
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Scott D. Sandell
Date:08/11/2025
Paul Walker
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Paul Walker
Date:08/11/2025
Comments accompanying signature:
This Amendment No. 7 to Schedule 13D was executed by Zachary Bambach on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which is attached as Exhibit 2.

FAQ

How many Trevi Therapeutics (TRVI) shares do NEA and affiliates beneficially own?

The filing reports that the Reporting Persons collectively beneficially own 15,074,080 shares, representing 12.0% of the class on the basis stated in the filing.

What is NEA 16's position in TRVI according to the amendment?

NEA 16 is the record owner of 10,421,428 shares and holds warrants exercisable for 3,703,704 shares, which the filing treats as part of its potential beneficial ownership.

Did the reporting persons disclose any plans to change Trevi's management or take corporate actions?

No. The filing states the Funds have no present plans to effect board changes, asset sales, extraordinary transactions, changes to capitalization, or similar actions.

Why did NEA's percentage ownership decrease in this amendment?

The amendment reports the percentage decrease resulted from an increase in the number of Trevi common shares outstanding, not from sales by the reporting persons.

Have the reporting persons made any transactions in the last 60 days?

The filing states that none of the Reporting Persons effected any transaction in the last 60 days.
Trevi Therapeutics

NASDAQ:TRVI

TRVI Rankings

TRVI Latest News

TRVI Latest SEC Filings

TRVI Stock Data

1.37B
113.69M
0.72%
92.78%
9.6%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW HAVEN